Free Trial

Geron (NASDAQ:GERN) Now Covered by The Goldman Sachs Group

Geron logo with Medical background

The Goldman Sachs Group initiated coverage on shares of Geron (NASDAQ:GERN - Free Report) in a research note released on Thursday, Marketbeat reports. The brokerage issued a sell rating and a $1.00 target price on the biopharmaceutical company's stock.

Several other equities research analysts have also recently weighed in on the stock. Needham & Company LLC restated a "buy" rating and issued a $5.00 price objective on shares of Geron in a research report on Wednesday, March 12th. HC Wainwright restated a "neutral" rating on shares of Geron in a research report on Wednesday, March 12th. Finally, Scotiabank cut shares of Geron from a "sector outperform" rating to a "sector perform" rating and lowered their price target for the stock from $4.00 to $1.50 in a research report on Thursday, May 8th. Two analysts have rated the stock with a sell rating, three have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Geron currently has an average rating of "Hold" and a consensus price target of $4.61.

Get Our Latest Stock Report on Geron

Geron Price Performance

GERN traded down $0.06 during midday trading on Thursday, hitting $1.38. The company had a trading volume of 12,003,741 shares, compared to its average volume of 11,298,577. The company has a debt-to-equity ratio of 0.44, a quick ratio of 6.97 and a current ratio of 7.87. The company has a market capitalization of $878.95 million, a PE ratio of -6.57 and a beta of 0.64. Geron has a twelve month low of $1.17 and a twelve month high of $5.06. The firm's 50-day simple moving average is $1.44 and its 200-day simple moving average is $1.96.

Geron (NASDAQ:GERN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.01. The firm had revenue of $39.60 million during the quarter, compared to analysts' expectations of $49.88 million. Geron had a negative net margin of 119.54% and a negative return on equity of 47.86%. The company's quarterly revenue was up 12927.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.07) EPS. Equities research analysts predict that Geron will post -0.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of GERN. SBI Securities Co. Ltd. acquired a new position in Geron during the fourth quarter valued at approximately $28,000. Frisch Financial Group Inc. grew its holdings in Geron by 84.3% during the first quarter. Frisch Financial Group Inc. now owns 19,025 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 8,700 shares during the period. Integrated Wealth Concepts LLC acquired a new position in Geron during the fourth quarter valued at approximately $36,000. Focus Partners Advisor Solutions LLC acquired a new position in Geron during the first quarter valued at approximately $39,000. Finally, Sowell Financial Services LLC acquired a new position in Geron during the first quarter valued at approximately $43,000. Institutional investors and hedge funds own 73.71% of the company's stock.

About Geron

(Get Free Report)

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

Further Reading

Analyst Recommendations for Geron (NASDAQ:GERN)

Should You Invest $1,000 in Geron Right Now?

Before you consider Geron, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.

While Geron currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines